BPC-157 Alternatives Without Theoretical Cancer Risk: Pro-Angiogenic Concerns and Safer Peptide Options BPC-157 promotes blood vessel growth in animal studies, raising theoretical concerns about feeding occult tumors
Additionally, tesamorelin side effects include joint pain, muscle aches, and peripheral edema
Like BPC-157, GHK-Cu appears to coordinate a complex mechanism of protein deposition and breakdown via gene regulation
The total human evidence base, as of this writing, consists of the following: 1) a Phase I safety trial of 42 healthy volunteers that was registered in 2015, canceled in 2016, and never published, 2) a retrospective case series of 12 patients with knee pain, no control group, and no validated outcome measure, and 3) a 2025 pilot safety study involving two healthy adults who received intravenous infusions at a single private clinic in Florida